Algahtani Hussein, Marghalani Siham, Satti Mohamed, Shirah Bader
Division of Neurology, Department of Medicine, King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
J Epilepsy Res. 2017 Dec 31;7(2):106-108. doi: 10.14581/jer.17016. eCollection 2017 Dec.
Levetiracetam is one of the newer second-generation antiepileptic drugs with multiple mechanisms of action. Cutaneous side effects due to levetiracetam are rarely reported in the literature. In this article, we describe a patient with skin hyperpigmentation due to the treatment with levetiracetam with complete resolution after discontinuation of the medication. In addition, we review the topic and hypothesize the mechanism behind this rare complication. To the best of our knowledge, this is the first report of skin hyperpigmentation as a side effect of levetiracetam in the literature. The prescribing physicians should inform the patients about all potential side effect of levetiracetam including skin hyperpigmentation. Similar to many undiagnosed conditions, increased awareness of their existence is the key to diagnosis. Early recognition and timely cessation of therapy are important to reverse this effect. Further studies should be conducted to explore the pathophysiology of this rare side effect.
左乙拉西坦是一种新型的第二代抗癫痫药物,具有多种作用机制。文献中很少报道左乙拉西坦引起的皮肤副作用。在本文中,我们描述了一名因使用左乙拉西坦治疗而出现皮肤色素沉着的患者,停药后色素沉着完全消退。此外,我们回顾了该主题并推测了这种罕见并发症背后的机制。据我们所知,这是文献中首次报道左乙拉西坦引起皮肤色素沉着作为副作用。开处方的医生应告知患者左乙拉西坦的所有潜在副作用,包括皮肤色素沉着。与许多未确诊的疾病一样,提高对其存在的认识是诊断的关键。早期识别和及时停药对于逆转这种效应很重要。应进行进一步研究以探索这种罕见副作用的病理生理学。